Bremelanotide Guide

Bremelanotide is a synthetic cyclic peptide and melanocortin receptor agonist. In the United States, the FDA-approved prescription product is Vyleesi, a single-dose autoinjector for subcutaneous administration. [1][2]

The approved indication is narrow: treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD, when low sexual desire causes marked distress or interpersonal difficulty and is not primarily explained by another medical or psychiatric condition, relationship problems, or medication or substance effects. [1][3]

That distinction matters because online discussions often use names like PT-141, bremelanotide, and Vyleesi interchangeably. The evidence and labeling apply to the FDA-approved product and studied trial populations, not to unverified research products, compounded products, or off-label consumer protocols. [1][4][7]

The Vyleesi label describes bremelanotide as a melanocortin receptor agonist that nonselectively activates several melanocortin receptor subtypes. The label lists potency in the order MC1R, MC4R, MC3R, MC5R, and MC2R, while stating that MC1R and MC4R binding is most relevant at therapeutic dose levels. [1]

MC4R-expressing neurons are present in many areas of the central nervous system. Even so, the official label is careful: the precise mechanism by which Vyleesi improves HSDD in women is unknown. [1]

MC1R is expressed on melanocytes. Binding at this receptor can increase melanin expression and pigmentation, which helps explain why focal hyperpigmentation appears in the labeled safety warnings. [1]

Bremelanotide is sometimes framed online as a libido peptide, but the studied mechanism is not the same as a direct vascular erectile-dysfunction drug, a hormone-replacement therapy, or a general sexual-performance enhancer. The approved use is based on patient-reported desire and distress outcomes in a defined HSDD population. [1][4][6]

FDA approved Vyleesi under NDA 210557 in 2019 for treatment of premenopausal women with acquired, generalized HSDD. The approval letter states that FDA completed review of the application and approved it for use as recommended in the agreed labeling. [3]

The pivotal evidence base in labeling is two identical Phase 3, randomized, double-blind, placebo-controlled trials, identified as NCT02333071 and NCT02338960. The studies enrolled premenopausal women with acquired, generalized HSDD of at least six months duration and evaluated a 24-week double-blind period followed by an open-label extension. [1][4]

The coprimary endpoints were change in the Female Sexual Function Index desire domain and change in distress related to low sexual desire measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm item 13. These are patient-reported outcomes, so the result should be interpreted as changes in desire and distress scores rather than a guaranteed change in sexual events or relationship outcomes. [1][4][6]

Vyleesi labeling also includes a discontinuation framework: if symptoms do not improve after a trial period specified in the label, treatment should be stopped. That is a clinician-label context, not a self-directed protocol. [1][2]

In both pivotal studies summarized in the prescribing information, Vyleesi showed statistically significant improvement versus placebo on the FSFI desire domain and statistically significant reduction in distress related to low sexual desire on FSDS-DAO question 13. [1][4]

The magnitude of benefit was modest in absolute score changes. In labeling, mean FSFI desire-domain changes were larger with Vyleesi than placebo, and distress scores decreased more with Vyleesi than placebo, but these were group-level questionnaire outcomes rather than an individual prediction. [1][4][6]

The label reports no significant difference between treatment groups in the change from baseline in the number of satisfying sexual events, a secondary endpoint. This is an important guardrail against oversimplified claims that bremelanotide automatically improves sexual frequency or performance. [1]

A long-term open-label extension followed participants after the controlled phase. It is useful for safety and persistence context, but because it was uncontrolled, it cannot answer the same efficacy question as the randomized placebo-controlled period. [5]

The most important labeled contraindications are uncontrolled hypertension and known cardiovascular disease. Labeling also warns that bremelanotide can transiently increase blood pressure and reduce heart rate after each dose, usually resolving within 12 hours. [1][2]

Focal hyperpigmentation is a labeled warning. The label reports hyperpigmentation in about 1% of patients using up to the labeled monthly maximum, including involvement of the face, gums, and breasts. Risk is described as higher in people with darker skin and with daily use, and resolution was not confirmed in some patients. [1][2]

Nausea is common and can be severe. In the prescribing information, nausea was reported by 40% of patients using up to the labeled monthly maximum, required antiemetic therapy in 13%, and led to premature discontinuation in 8%. Other common adverse reactions include flushing, injection-site reactions, headache, and vomiting. [1][2]

Vyleesi may slow gastric emptying and affect absorption of oral medicines. The label specifically says to avoid use with oral naltrexone-containing products intended to treat alcohol or opioid addiction because bremelanotide may significantly reduce naltrexone exposure. [1]

Pregnancy and reproductive-potential warnings are also part of the label. Patients are advised to discontinue Vyleesi if pregnancy is suspected and to use effective contraception while taking it. Safety has not been established for pediatric use, and labeling includes additional considerations for renal and hepatic impairment. [1][2]

Official storage instructions for Vyleesi state to store at or below 77 degrees F, which is 25 degrees C. The label also says not to freeze the product and to protect it from light. [1][2]

The product is supplied as a sterile, clear solution in a prefilled syringe contained in a single-dose disposable autoinjector. Each autoinjector is a finished drug-device product, so its handling instructions should not be generalized to research powders, compounded vials, or products marketed only as PT-141. [1][2]

Patient labeling says the medicine in the view window should be clear and free of particles, and that it should not be used if cloudy, discolored, or particle-containing. Those are product-quality checks from the approved autoinjector labeling, not a preparation guide. [2]

There is no official FDA-approved reconstitution standard for consumer bremelanotide research powders. Any storage or preparation instructions from non-approved sellers should be treated as product-specific claims, not as evidence that the material is equivalent to Vyleesi. [1][3][7]